bpc 157 tb 500 and cjc 1295 fda approval status of bpc-157 tb-500 ipamorelin cjc-1295 Robert F. Kennedy Jr. says Investigating Peptide Combinations for Advanced

BPC-157 and TB-500 are synthetic peptides that have gained attention within research and bio-science communities for their potential involvement in cellular repair processes, inflammation signalling, and tissue adaptation pathways

- Most evidence comes from animal studies - Human data is extremely limited - No FDA approval for orthopedic use - Clinical benefit in musculoskeletal conditions remains unproven While the biology is interesting, potential does not equal proven clinical outcomes

severe gastroparesis

Long-term oncologic safety remains an open research question because the same migration-promoting and pro-angiogenic activity that supports wound closure has, in some murine melanoma models, correlated with increased metastasis